Rontalizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRontalizumab
Drug Alias Name罗利珠单抗rontalizumabum隆他利珠单抗rhuMAb IFN alphaRG-7415 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterferon alpha inhibitors
TargetsInterferon alpha
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandMexico +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG